期刊文献+

我国呼吸机相关性肺炎发病危险因素的Meta分析 被引量:11

Risk factors of ventilator associated pneumonia:a Meta-analysis in China
原文传递
导出
摘要 目的:综合评价国内呼吸机相关性肺炎(ventilator associated pneumonia,VAP)发病的危险因素。方法:通过国内外数据库检索中国发表的VAP危险因素的相关研究,用Meta分析的方法对入选文献进行定量综合分析;用固定效应模型或随机效应模型计算OR值及95%CI。结果:总共14篇相关文献入选本研究,累计病例691例,对照病例1 145例;在分析的9个危险因素中有5个因素差异具有统计学意义,与VAP相关的危险因素及其OR值分别为:预防性抗菌药物使用(OR=6.60,95%CI:3.01~14.50)、气管切开(OR=4.25,95%CI:2.32~7.76)、鼻胃管留置(OR=3.09,95%CI:1.85~5.16)、胃肠内营养(OR=3.44,95%CI:1.22~9.68)、糖皮质激素应用(OR=3.28,95%CI:1.68~6.38)。结论:应针对国内VAP发病相关的危险因素采取针对性预防措施,从而降低VAP的发生率。 Objective:To synthetically evaluate the risk factors of ventilator associated pneumonia (VAP) in China. Methods:The relative researches of VPA were searched by domestic and abroad literature database, and literatures published in China selected were quantitatively analyzed by Meta-analysis. The pooled OR and its corresponding 95% CI were calculated by fixed effect model or random effect model. Results: Fourteen relative literatures were selected in this study,including 691 patients and 1 145 controls. Among nine risk factors, five factors had statistical significances. Risk factors of VAP and its value of OR were as follows:prophylactic antibiotic use ( OR =6.60,95% CI : 3.01 N 14.50), tracheostomy ( OR =4.25,95% CI : 2.32 N7.76), nasal and gastric tube ( OR =3.09,95% CI : 1.85 -5.16), enteral nutrition (OR =3.44,95% CI : 1.22 -9.68), glucocorticoid use ( OR =3.28,95% CI: 1.68 ~6.38). Conclusion: Special methods should be taken, according to the risk factors of VAP, to decrease the incidence rate of VAP in China.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2012年第11期1621-1625,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏高校优势学科建设工程资助(JX10231801)
关键词 呼吸机相关性肺炎 危险因素 META分析 ventilator associated pneumonia risk factors Meta-analysis
  • 相关文献

参考文献23

二级参考文献97

共引文献393

同被引文献138

  • 1曾宗鼎,邢崇浩.降阶梯方案治疗呼吸科重症监护病房老年重症肺炎患者的临床疗效[J].中国老年学杂志,2014,34(8):2270-2272. 被引量:35
  • 2刘大为,邱海波.重症医学-2011[M].北京:人民卫生出版社,2011:239-244.
  • 3Torres A,Ferrer M,Badia JR,et al.Treatment guidelines andoutcomes of hospital-acquired and ventilator-associated pneumonia[J].Clin Infect Dis,2010,51suppl1:S48-S53.
  • 4Shraf M,Ostrosky-Zeichner L.Ventilator-associated pneumonia:areview[J].Hosp Pract(Minneap),2012,40(1):93-105.
  • 5Palmer LB.Ventilator-associated infection[J].Curr Opin PulmMed,2009,15(3):230-235.
  • 6丛玉隆,王鸿利,仲人前,等.实用检验医学(上册)[M].第1版.北京:人民卫生出版社,2009.
  • 7Pachon J,Vila J.Treatment of multiresistant Acinetobacterbaumannii infections[J].Curr Ovin Investig Invest Drugs,2009,10(2):150-156.
  • 8Coppadoro A,Berra L,Bigatello LM.Modifying endotrachealtubes to prevent ventilator-associated pneumonia[J].Curr OpinInfect Dis,2011,24(2):157-162.
  • 9Levy MM. A New Definition of Ventilator-associated Pneu- monia:Far from Perfect, Better Than Before [J]. Ann Am Thorac Soc, 2013,10(6) :644-645.
  • 10Lahoorpour F, Delpisheh A, Afkhamzadeh A. Risk fac- tors for acquisition of ventilator-associated pneumonia in adult intensive care units [J]. Pak J Med Sci,2013,29(5): 1105-1107.

引证文献11

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部